Molecular Metabolism · Nov 3, 2026

Discovery, optimization, and Phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist

By Mowery SA, Knerr PJ, Hjøllund KR et al.

Objective The efficacy and convenience of anti-diabetic and anti-obesity therapeutics have surged in recent years due to the emergence of incretin-based poly-pharmacological approaches as well as advances in the oral delivery of peptide drugs. We sought to combine both strategies in an orally deliverable dual agonist of the GLP-1 and GIP receptors. Methodology We designed a panel of unimolecular, fatty-acylated peptide dual agonists, which was screened for receptor potencies in cell-based assay systems. NNC0130 was selected to advance into clinical studies using both oral and subcutaneous administration. Results NNC0130 exhibited in vitro potency comparable to semaglutide at human GLP-1R and to tirzepatide at human GIPR, with a chemical structure compatible with semi-recombinant production. Its human half-life of 76-89 hours was deemed suitable for once-daily oral administration. In a multiple-ascending dose trial in participants with overweight or obesity and with separate subcutaneous and oral cohorts, daily subcutaneous administration of NNC0130 escalating from 0.3 to 3.0 mg per dose provided a placebo-corrected mean body weight loss of 9% after 12 weeks of treatment and 12% after 15 weeks. Daily oral administration escalating from 5 to 50 mg per dose provided a placebo-corrected mean body weight loss of 4% after 12 weeks, which was not statistically significantly different from zero. The relative oral bioavailability when co-formulated with permeation enhancer salcaprozate sodium was estimated to 1.6-2.2% versus s.c. administration. Conclusions The modest weight lowering efficacy of orally administered NNC0130 highlights the continued challenges of low oral bioavailability of acylated peptides. However, the substantial efficacy observed with subcutaneous administration motivated advancement into Phase 2 clinical development.

doi.org/10.1016/j.molmet.2026.102470Open accessPubMed 42977258Interventions

AgingResearch.News